H. Khong

发表

Natural selection of tumor variants in the generation of “tumor escape” phenotypes

N. Restifo, H. Khong, 2002, Nature Immunology.

miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20

Ming Zhou, M. Tan, H. Khong, 2016, Oncotarget.

Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression

S. Rosenberg, H. Khong, Qiong J. Wang, 2004, Journal of immunotherapy.

Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma

A. Ray, H. Khong, Junjie Ma, 2018, Scientific Reports.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study

B. Czerniecki, N. Tran, Hyo S Han, 2021, Advances in radiation oncology.

The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.

S. Rosenberg, H. Khong, 2002, Cancer research.

Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen

S. Rosenberg, J. Yang, S. Topalian, 2004, Journal of immunotherapy.

Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis

H. Khong, Junjie Ma, Luke G. Mirabelli, 2017, Oncotarget.

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

P. Neven, A. Bardia, F. Bidard, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activated CD4+ T Cells Dramatically Enhance Chemotherapeutic Tumor Responses In Vitro and In Vivo

Yixiang Wang, H. Khong, S. Radfar, 2009, The Journal of Immunology.

Responses In Vitro and In Vivo Enhance Chemotherapeutic Tumor T Cells Dramatically + Activated CD4

Yixiang Wang, H. Khong, S. Radfar, 2009 .

Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.

N. Senzer, J. Nemunaitis, M. Morse, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer

B. Czerniecki, B. Niell, S. Hoover, 2020, Clinical Cancer Research.

Activated CD4+ T cells enhance radiation effect through the cooperation of interferon-γ and TNF-α

Yixiang Wang, H. Khong, S. Radfar, 2010, BMC Cancer.

Transduction of an HLA-DP4–restricted NY-ESO-1–specific TCR into Primary Human CD4+ Lymphocytes

S. Rosenberg, R. Morgan, Yangbing Zhao, 2006, Journal of immunotherapy.

Molecular and Functional Analysis of Tyrosinase-Related Protein (TRP)-2 as a Cytotoxic T Lymphocyte Target in Patients With Malignant Glioma

K. Black, Gentao Liu, H. Khong, 2003, Journal of immunotherapy.

Pre-Existing Immunity to Tyrosinase-Related Protein (TRP)-2, a New TRP-2 Isoform, and the NY-ESO-1 Melanoma Antigen in a Patient with a Dramatic Response to Immunotherapy

S. Rosenberg, H. Khong, 2002, The Journal of Immunology.

with a Dramatic Response to Immunotherapy the NY-ESO-1 Melanoma Antigen in a Patient Protein (TRP)-2, a New TRP-2 Isoform, and Pre-Existing Immunity to Tyrosinase-Related

S. Rosenberg, H. Khong, 2001 .

Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression

S. Rosenberg, P. Robbins, M. Dudley, 2005, Journal of immunotherapy.

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia

James X. Sun, B. Czerniecki, S. Hoover, 2021, Cancer medicine.

Advances in Brief The Waardenburg Syndrome Type 4 Gene , SOX 10 , Is a Novel Tumor-associated Antigen Identified in a Patient with a Dramatic Response to Immunotherapy

S. Rosenberg, H. Khong, 2002 .

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

D. Boulware, M. Extermann, H. Khong, 2019, The oncologist.

A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors.

A. Ray, A. Cohen, H. Khong, 2017, Oncotarget.

A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer.

A. Ray, H. Khong, B. Khong, 2016, Anticancer research.

A Phase I Study of Neoadjuvant Chemotherapy With Nab‐Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer

L. Neumayer, S. Buys, A. Ray, 2017, Clinical breast cancer.

Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2

A. Ray, H. Khong, Junjie Ma, 2018, BMC Cancer.

Identification of Endogenous HLA-A2–Restricted Reactivity Against Shared Melanoma Antigens in Patients Using the Quantitative Real-Time Polymerase Chain Reaction

S. Rosenberg, U. Kammula, H. Khong, 2002, Journal of immunotherapy.

A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes

B. Czerniecki, D. Boulware, L. Loftus, 2021, Breast cancer.

Thrombotic Microangiopathy: A Rare Breast Cancer-associated Complication Treated Successfully With Doxorubicin and Cyclophosphamide

H. Khong, A. Tandon, S. Jalali, 2021, In Vivo.

Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.

H. Khong, T. W. Butler, A. Hahn, 2017, Molecular and clinical oncology.

Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma

Yixiang Wang, H. Khong, A. Riker, 2010, BMC medicine.

Immunotherapy of melanoma: a critical review of current concepts and future strategies

Yixiang Wang, H. Khong, A. Riker, 2007, Expert opinion on biological therapy.

Demethylating Agents in the Treatment of Cancer

H. Khong, P. Howell, Zixing Liu, 2010, Pharmaceuticals.

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

B. Czerniecki, B. Niell, S. Hoover, 2023, Nature Medicine.

Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy

K. Black, Gentao Liu, A. Das, 2005, Oncogene.

miR-125b Functions as a Key Mediator for Snail-induced Stem Cell Propagation and Chemoresistance*

Ming Tan, Zixing Liu, Ming Zhou, 2012, The Journal of Biological Chemistry.

Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ.

S. Florell, T. Bowles, K. Duffy, 2014, Journal of the American Academy of Dermatology.

Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth

M Tan, Dihua Yu, Yan Ding, 2009, Oncogene.

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

C. Klebanoff, N. Restifo, D. Palmer, 2005, Trends in immunology.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis

A. Cohen, M. McMahon, S. Holmen, 2017, Melanoma research.

Chemocentric Chemoimmunotherapy: A New Concept in Melanoma Immunotherapy

Yixiang Wang, H. Khong, P. Howell, 2011 .

Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines

Richard A. Morgan, Steven A. Rosenberg, Yangbing Zhao, 2005, The Journal of Immunology.

The immune checkpoint kick start: Optimization of neoadjuvant combination therapy using game theory

Drew F. K. Williamson, Joel s. Brown, H. Khong, 2018, bioRxiv.

Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma

A. Ray, H. Khong, Junjie Ma, 2018, Scientific Reports.

Sentinel Lymph Node Biopsy for Melanoma in Pregnant Women

S. Leachman, S. Florell, T. Bowles, 2013, Annals of Surgical Oncology.

Generating Renal Cancer-Reactive T Cells Using Dendritic Cells (DCs) to Present Autologous Tumor

J. Yang, T. Karpova, M. Bettinotti, 2005, Journal of immunotherapy.

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma

A. Ray, S. Leachman, S. Holmen, 2016, Oncotarget.

A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors

A. Ray, A. Cohen, H. Khong, 2016, Oncotarget.

Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01.

A. Bardia, T. Traina, M. Danso, 2017 .

Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

P. Neven, A. Bardia, F. Bidard, 2023, Cancer Research.

Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status

W. Sause, T. Bowles, D. Grossman, 2020, Melanoma research.

Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.

M. Ross, A. Daud, R. Ungerleider, 2017 .

Abstract LB-175: Phase II study of disulfiram and chelated Zn for the treatment of disseminated metastatic melanoma.

K. Boucher, K. Grossmann, H. Khong, 2013 .

645 Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC)

B. Czerniecki, F. Locke, L. Loftus, 2022, Regular and Young Investigator Award Abstracts.

A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma.

S. Leachman, S. Holmen, M. VanBrocklin, 2015 .

A phase I study of neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel, doxorubicin, and cyclophosphamide (NAC) in patients with stages II-III HER2-negative breast cancer.

H. Khong, T. W. Butler, D. Dyess, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of abemaciclib (abema) after palbociclib (palbo) in patients (pts) with metastatic breast cancer (MBC).

D. Boulware, R. Costa, H. Khong, 2019, Journal of Clinical Oncology.

Evolutionary exploitation of PD-L1 expression in hormone receptor positive breast cancer

Drew F. K. Williamson, P. Ashcroft, D. Maestrini, 2018, bioRxiv.

Fatal Allograft Rejection and Cardiac Allograft Vasculopathy After Treatment With Pembrolizumab for Metastatic Melanoma in a Heart Transplant Recipient: A Case Report.

O. Wever-Pinzon, J. Fang, M. Revelo, 2022, Transplantation Proceedings.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.

N. Senzer, M. Morse, J. Stephenson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

This information is current as Responses In Vitro and In Vivo Enhance Chemotherapeutic Tumor T Cells Dramatically + Activated CD 4

Yixiang Wang, H. Khong, S. Radfar, 2009 .